var data={"title":"Lamotrigine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Lamotrigine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6426?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">see &quot;Lamotrigine: Drug information&quot;</a> and <a href=\"topic.htm?path=lamotrigine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Lamotrigine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709006\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Serious skin rashes:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Lamotrigine can cause serious rashes requiring hospitalization and discontinuation of treatment. The incidence of these rashes, which have included Stevens-Johnson syndrome, is approximately 0.3% to 0.8% in pediatric patients (2 to 17 years of age) and 0.08% to 0.3% in adults receiving lamotrigine. One rash-related death was reported in a prospectively followed cohort of 1,983 pediatric patients (2 to 16 years of age) with epilepsy taking lamotrigine immediate-release as adjunctive therapy. In worldwide postmarketing experience, rare cases of toxic epidermal necrolysis and/or rash-related death have been reported in adults and pediatric patients, but those numbers are too few to permit a precise estimate of the rate. </p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">The risk of serious rash caused by treatment with lamotrigine ER is not expected to differ from that with the immediate-release formulation of lamotrigine. However, the relatively limited treatment experience with lamotrigine ER makes it difficult to characterize the frequency and risk of serious rashes caused by treatment with lamotrigine ER. Lamotrigine ER is not approved for patients younger than 13 years.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Other than age, there are as yet no factors identified that are known to predict the risk of occurrence or the severity of rash caused by lamotrigine. There are suggestions, yet to be proven, that the risk of rash may also be increased by coadministration of lamotrigine with valproate (includes valproic acid and divalproex sodium), exceeding the recommended initial dose of lamotrigine, or exceeding the recommended dose escalation for lamotrigine. However, cases have been reported in the absence of these factors.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Nearly all cases of life-threatening rashes associated with lamotrigine have occurred within 2 to 8 weeks of treatment initiation. However, isolated cases have been reported after prolonged treatment (eg, 6 months). Accordingly, duration of therapy cannot be relied upon as a means to predict the potential risk heralded by the first appearance of a rash.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Although benign rashes are also caused by lamotrigine, it is not possible to predict reliably which rashes will prove to be serious or life-threatening. Accordingly, lamotrigine should ordinarily be discontinued at the first sign of rash unless the rash is clearly not drug-related. Discontinuation of treatment may not prevent a rash from becoming life-threatening or permanently disabling or disfiguring.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186304\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>LaMICtal;</li>\n      <li>LaMICtal ODT;</li>\n      <li>LaMICtal Starter;</li>\n      <li>LaMICtal XR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186305\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Lamotrigine;</li>\n      <li>Auro-Lamotrigine;</li>\n      <li>Lamictal;</li>\n      <li>Mylan-Lamotrigine;</li>\n      <li>PMS-Lamotrigine;</li>\n      <li>ratio-Lamotrigine;</li>\n      <li>Teva-Lamotrigine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053553\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Anticonvulsant, Miscellaneous</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12675197\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosage depends on patient's concomitant medications (ie, valproic acid; enzyme-inducing AEDs [specifically phenytoin, phenobarbital, carbamazepine, and primidone]; or AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid). Patients receiving concomitant rifampin or other drugs that induce lamotrigine glucuronidation and increase clearance should follow the same dosing regimen as that used with anticonvulsants that have this effect (eg, phenytoin, phenobarbital, carbamazepine, and primidone). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anticonvulsant: Adjunctive (add-on) therapy for refractory seizures:</b> Limited data available: Oral: PNA 14 to 28 days: Immediate release: Initial: 2 mg/kg/dose once daily; may increase by 2 mg/kg/day at intervals of at least 7 days to a maximum dose of 10 mg/kg/day; this dosing was described in a prospective, open-label trial that included five neonates (GA not reported) in the study population; all patients had previously received enzyme-inducing agents, such as phenytoin, phenobarbital, and/or carbamazepine; patients were treated with lamotrigine for 3 months (Mikati 2002)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053546\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">see &quot;Lamotrigine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Tablets should not be split to achieve dose; whole tablets should be used for dosing; round calculated dose down to the nearest whole tablet. Alternatively, a suspension may be prepared using immediate release tablets (see Extemporaneous Preparations). Dosage depends on patient's concomitant medications [ie, valproic acid; enzyme-inducing AEDs (specifically phenytoin, phenobarbital, carbamazepine, and primidone); or other AEDs not previously mentioned. Patients receiving concomitant rifampin or other drugs that induce lamotrigine glucuronidation and increase clearance should follow the same dosing regimen as that used with anticonvulsants that have similar effects (eg, phenytoin, phenobarbital, carbamazepine, and primidone).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anticonvulsant: Lennox-Gastaut syndrome, primary generalized tonic-clonic seizures, or partial seizures; adjunctive (add-on) therapy:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <span style=\"text-decoration: underline\">Immediate-release formulations:</span></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &lt;24 months: Adjunctive therapy; partial seizures: Limited data available (Pi&ntilde;a-Garza 2008; Pi&ntilde;a-Garza 2008a): <b>Note:</b> As reported in the trials, initial doses were administered every other day if necessary due to limited strengths of commercially available products; use of an extemporaneously compounded suspension may allow for more frequent dosing; usually, daily doses are divided into 1 to 2 doses per day; daily doses in these trials were divided 3 times daily once sufficiently large enough to utilize commercially available products; this was done due to the possible increased clearance of lamotrigine in this age group.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Patients receiving AED regimens <b>containing valproic acid or nonenzyme-inducing </b> AEDs:</i> <b>Note:</b> Studies excluded patients &lt;6.7 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Weeks 1 and 2: 0.15 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Weeks 3 and 4: 0.3 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Maintenance dose: Titrate dose to effect; after week 4, increase dose every week by no more than 0.3 mg/kg/day; maximum maintenance dose: 5.1 mg/kg/day in 3 divided doses not to exceed 200 mg/day; mean final dose required in open-label phase of trial was 3.1 mg/kg/day; n=51 (Pi&ntilde;a-Garza 2008a)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Patients receiving <b>enzyme-inducing</b> AED regimens (eg, carbamazepine, phenytoin, phenobarbital, or primidone) <b>without valproic acid</b>: </i></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Weeks 1 and 2: 0.6 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Weeks 3 and 4: 1.2 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Maintenance dose: Titrate dose to effect; after week 4, increase dose every week by no more than 1.2 mg/kg/day; maximum maintenance dose: 15.6 mg/kg/day in 3 divided doses not to exceed 400 mg/day; mean final dose required in open-label phase of trial was 8.9 mg/kg/day; n=126 (Pi&ntilde;a-Garza 2008a)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 2 to 12 years: <b>Note:</b> <b> Only whole tablets should be used for dosing</b>; children 2 to 6 years will likely require maintenance doses at the higher end of recommended range; patients weighing &lt;30 kg may need as much as a 50% increase in maintenance dose compared with patients weighing &gt;30 kg; titrate dose to clinical effect</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Patients receiving AEDs <span style=\"text-decoration: underline\">other than</span></i> <b><i> carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Weeks 1 and 2: 0.3 mg/kg/day in 1 to 2 divided doses; round dose down to the nearest whole tablet</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Weeks 3 and 4: 0.6 mg/kg/day in 2 divided doses; round dose down to the nearest whole tablet</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Maintenance dose: Titrate dose to effect; after week 4, increase dose every 1 to 2 weeks by a calculated increment; calculate increment as 0.6 mg/kg/day rounded down to the nearest whole tablet; add this amount to the previously administered daily dose; usual maintenance: 4.5 to 7.5 mg/kg/day in 2 divided doses; maximum daily dose: 300 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Patients receiving AED regimens <b>containing valproic acid</b>:</i></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Weeks 1 and 2: 0.15 mg/kg/day in 1 to 2 divided doses; round dose down to the nearest whole tablet; use 2 mg every other day for patients weighing &gt;6.7 kg and &lt;14 kg</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Weeks 3 and 4: 0.3 mg/kg/day in 1 to 2 divided doses; round dose down to the nearest whole tablet</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Maintenance dose: Titrate dose to effect; after week 4, increase dose every 1 to 2 weeks by a calculated increment; calculate increment as 0.3 mg/kg/day rounded down to the nearest whole tablet; add this amount to the previously administered daily dose; usual maintenance: 1 to 5 mg/kg/day in 1 to 2 divided doses; maximum daily dose: 200 mg/day. <b>Note:</b> Usual maintenance dose in children adding lamotrigine to valproic acid <b>alone</b>: 1 to 3 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Patients receiving <b>enzyme-inducing</b> AED regimens (eg, carbamazepine, phenytoin, phenobarbital, or primidone) <b>without valproic acid</b>: </i></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Weeks 1 and 2: 0.6 mg/kg/day in 2 divided doses; round dose down to the nearest whole tablet</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Weeks 3 and 4: 1.2 mg/kg/day in 2 divided doses; round dose down to the nearest whole tablet</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Maintenance dose: Titrate dose to effect; after week 4, increase dose every 1 to 2 weeks by a calculated increment; calculate increment as 1.2 mg/kg/day rounded down to the nearest whole tablet; add this amount to the previously administered daily dose; usual maintenance: 5 to 15 mg/kg/day in 2 divided doses; maximum daily dose: 400 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Patients receiving AEDs <span style=\"text-decoration: underline\">other than</span></i> <b><i> carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Weeks 1 and 2: 25 mg every day</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Weeks 3 and 4: 50 mg every day</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Maintenance dose: Titrate dose to effect; after week 4, increase dose every 1 to 2 weeks by 50 mg/day; usual maintenance: 225 to 375 mg/day in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Patients receiving AED regimens <b>containing valproic acid</b>: </i></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Weeks 1 and 2: 25 mg every other day</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Weeks 3 and 4: 25 mg every day</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Maintenance dose: Titrate dose to effect; after week 4, increase dose every 1 to 2 weeks by 25 to 50 mg/day; usual maintenance in patients receiving valproic acid and other drugs that induce glucuronidation: 100 to 400 mg/day in 1 to 2 divided doses; usual maintenance in patients adding lamotrigine to valproic acid <b>alone</b>: 100 to 200 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Patients receiving <b>enzyme-inducing</b> AED regimens (eg, carbamazepine, phenytoin, phenobarbital, or primidone) <b>without valproic acid</b>: </i></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Weeks 1 and 2: 50 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Weeks 3 and 4: 100 mg/day in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Maintenance dose: Titrate dose to effect; after week 4, increase dose every 1 to 2 weeks by 100 mg/day; usual maintenance: 300 to 500 mg/day in 2 divided doses; doses as high as 700 mg/day in 2 divided doses have been used</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <span style=\"text-decoration: underline\">Extended-release formulation:</span> Adolescents: <b>Note:</b> Dose increases after week 8 should not exceed 100 mg/day at weekly intervals</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Regimens <b>not containing</b> carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid:</i> Initial: Weeks 1 and 2: 25 mg once daily; Weeks 3 and 4: 50 mg once daily; Week 5: 100 mg once daily; Week 6: 150 mg once daily; Week 7: 200 mg once daily; Maintenance: 300 to 400 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Regimens <b>containing</b> valproic acid:</i> Initial: Weeks 1 and 2: 25 mg every other day; Weeks 3 and 4: 25 mg once daily; Week 5: 50 mg once daily; Week 6: 100 mg once daily; Week 7: 150 mg once daily; Maintenance: 200 to 250 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Regimens <b>containing</b> carbamazepine, phenytoin, phenobarbital, or primidone and <b>without</b> valproic acid:</i> Initial: Weeks 1 and 2: 50 mg once daily; Weeks 3 and 4: 100 mg once daily; Week 5: 200 mg once daily; Week 6: 300 mg once daily; Week 7: 400 mg once daily; Maintenance: 400 to 600 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>\n        <i>Conversion from immediate release to extended release (Lamictal XR):</i></b> Initial dose of the extended release tablet (given once daily) should match the total daily dose of the immediate release formulation; monitor for seizure control, especially in patients on AED agents. Adjust dose as needed within the recommended dosing guidelines.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">\n      <b>Anticonvulsant: Partial seizures; monotherapy:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <span style=\"text-decoration: underline\">Immediate-release formulations</span>: Adolescents &ge;16 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion from adjunctive therapy with a <b>single enzyme-inducing</b> AED (eg, carbamazepine, phenytoin, phenobarbital, or primidone and <b>not valproate</b>) to lamotrigine immediate release monotherapy:</i> <b>Note:</b> First add lamotrigine and titrate it (as outlined below) to the recommended maintenance monotherapy dose (500 mg/day in 2 divided doses), while maintaining the enzyme-inducing AED at a fixed level; then gradually taper the enzyme-inducing AED by 20% decrements each week to fully withdraw over a 4-week period.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Weeks 1 and 2: 50 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Weeks 3 and 4: 100 mg/day in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Maintenance dose: After week 4, increase dose every 1 to 2 weeks by 100 mg/day; recommended maintenance monotherapy dose: 500 mg/day in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion from adjunctive therapy with <b>valproate</b> to lamotrigine immediate release monotherapy:</i> <b>Note:</b> This is a 4-step conversion process to achieve the lamotrigine recommended monotherapy dose (500 mg/day in 2 divided doses).</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>First:</b> Add lamotrigine and titrate it to a dose of 200 mg/day as follows (if not already receiving 200 mg/day), while maintaining the valproate dose at a fixed level:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Weeks 1 and 2: 25 mg every other day</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Weeks 3 and 4: 25 mg every day</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Then increase dose every 1 to 2 weeks by 25 to 50 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>Second:</b> Keep lamotrigine dose at 200 mg/day; slowly taper valproate dose in decrements of &le;500 mg/day per week, to a dose of 500 mg/day; maintain this dose for one week</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>Third:</b> Increase lamotrigine to 300 mg/day and decrease valproate to 250 mg/day; maintain this dose for one week</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>Fourth:</b> Discontinue valproate and increase lamotrigine by 100 mg/day at weekly intervals to achieve recommended maintenance monotherapy dose of 500 mg/day in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion from adjunctive therapy with AEDs other than enzyme-inducing AEDs or valproate to lamotrigine immediate release monotherapy:</i> No specific guidelines available</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <span style=\"text-decoration: underline\">Extended-release formulation</span>: Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion from adjunctive therapy with AEDs <b>other than</b> enzyme-inducing AEDs or valproate to lamotrigine extended release monotherapy:</i> First add lamotrigine and titrate it (as outlined below) to a recommended lamotrigine dose of 250 to 300 mg once daily, while maintaining the concomitant AED at a fixed level; then gradually taper the concomitant AED by 20% decrements each week to fully withdraw over a 4-week period.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Weeks 1 and 2: 25 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Weeks 3 and 4: 50 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Week 5: 100 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Week 6: 150 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Week 7: 200 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Maintenance: 250 to 300 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion from adjunctive therapy with <b>valproate</b> to lamotrigine extended release monotherapy: </i>\n      <b>Note:</b> This is a 4-step conversion process to achieve the lamotrigine recommended extended release monotherapy dose (250 to 300 mg once daily).</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>First:</b> Add lamotrigine and titrate it to a dose of 150 mg/day as follows (if not already receiving 150 mg/day), while maintaining the valproate dose at a fixed level:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Weeks 1 and 2: 25 mg every other day</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Weeks 3 and 4: 25 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Week 5: 50 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Week 6: 100 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Week 7: 150 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>Second:</b> Keep lamotrigine dose at 150 mg/day; slowly taper valproate dose in decrements of &le;500 mg/day per week, to a dose of 500 mg/day; maintain this dose for 1 week</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>Third:</b> Increase lamotrigine to 200 mg/day and decrease valproate to 250 mg/day; maintain this dose for 1 week</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>Fourth:</b> Discontinue valproate and increase lamotrigine to a maintenance dose of 250 to 300 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion from adjunctive therapy with a <b>single enzyme-inducing</b> AED (eg, carbamazepine, phenytoin, phenobarbital, or primidone and <b>not valproate</b>) to lamotrigine extended release monotherapy in patients with partial seizures: </i>\n      <b>Note:</b> First add lamotrigine and titrate it (as outlined below) to a recommended lamotrigine dose of 500 mg/day, while maintaining the enzyme-inducing AED at a fixed level; then gradually taper the enzyme-inducing AED by 20% decrements each week to fully withdraw over a 4-week period. Two weeks following withdrawal of the enzyme-inducing AED, the dosage of lamotrigine extended release may be tapered in decrements of &le;100 mg/day at intervals of 1 week to achieve a maintenance dosage range of 250 to 300 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Weeks 1 and 2: 50 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Weeks 3 and 4: 100 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Maintenance: After week 4, increase dose every 1 week by 100 mg/day to a lamotrigine dose of 500 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">\n      <b>Anticonvulsant: Absence seizures; monotherapy:</b> Oral: Limited data available; efficacy results variable, optimal dose and titration not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <span style=\"text-decoration: underline\">Immediate-release formulations</span>: Children and Adolescents 2.5 to 13 years: Initial: 0.3 mg/kg/day in 2 divided doses for 2 weeks; then 0.6 mg/kg/day for 2 weeks; titrate weekly to effect/tolerability to a maximum daily dose of 12 mg/kg/day or 600 mg/day (whichever is less) (Glauser 2010; Glauser 2013). Multiple titration strategies have been reported. In the largest trial (n=453), the efficacy of lamotrigine (n=149) was compared with valproic acid (n=148) and ethosuximide (n=156); the initial lamotrigine dose was 0.3 mg/kg/day for 2 weeks, followed by 0.6 mg/kg/day for 2 weeks, then the dose was increased at weekly intervals until efficacy or intolerability in 0.6 mg/kg/day increments up to 3 mg/kg/day for 1 week (week 8), then increased to 4.5 mg/kg/day for 2 weeks, then 7 mg/kg/day for 2 weeks, then 9 mg/kg/day for 2 weeks, and then finally 12 mg/kg/day (week 15); mean final dose reported was 9.7 &plusmn; 6.3 mg/kg/day. Results showed the lamotrigine treatment arm had a treatment failure rate of 71%, compared to 47% failure with ethosuximide and 42% failure with valproic acid; the superior efficacy of valproic acid and ethosuximide persisted at 12 months (Glauser 2010; Glauser 2013). Another titration strategy based on two smaller studies used a higher initial dose of 0.5 mg/kg/day in 2 divided doses for 2 weeks, increased to 1 mg/kg/day for 2 weeks, then increased by 1 mg/kg/day increments every 5 days (or as clinically indicated) to a maximum of 12 mg/kg/day (Coppola 2004; Frank 1999). In one dose-escalation trial of 45 patients (2 to 15 years old), the median effective dose required was 5 mg/kg/day (range: 2 to 15 mg/kg/day) (Frank 1999). The other study was an open-label trial comparing lamotrigine (n=19) to valproic acid (n=19) in 3 to 13 year olds; the mean lamotrigine dose required at 3 months was 6.5 mg/kg/day (range: 2 to 11.5 mg/kg/day) (Coppola 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">\n      <b>Bipolar disorder:</b> Oral: <span style=\"text-decoration: underline\">Immediate-release formulation</span>: Adolescents &ge;18 years:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Patients <b>not</b> receiving enzyme-inducing drugs (eg, carbamazepine, phenytoin, phenobarbital, primidone, rifampin) or valproate: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weeks 1 and 2: 25 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weeks 3 and 4: 50 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Week 5: 100 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Week 6 and thereafter: 200 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Patients receiving <b>valproate</b>:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weeks 1 and 2: 25 mg every other day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weeks 3 and 4: 25 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Week 5: 50 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Week 6 and thereafter: 100 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> If valproate is discontinued, increase daily lamotrigine dose in 50 mg increments at weekly intervals until dosage of 200 mg/day is attained.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Patients receiving <b>enzyme-inducing drugs</b> (eg, carbamazepine, phenytoin, phenobarbital, primidone, rifampin) <b>without valproate</b>: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weeks 1 and 2: 50 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weeks 3 and 4: 100 mg/day in divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Week 5: 200 mg/day in divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Week 6: 300 mg/day in divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Week 7 and thereafter: May increase to 400 mg/day in divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> If carbamazepine (or other enzyme-inducing drug) is discontinued, maintain current lamotrigine dose for 1 week, then decrease daily lamotrigine dose in 100 mg increments at weekly intervals until dosage of 200 mg/day is attained.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lennox-Gastaut (adjunctive):</b> Oral: Immediate release formulation:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Regimens <b>not containing</b> carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid:</i> Initial: Weeks 1 and 2: 25 mg once daily; Weeks 3 and 4: 50 mg once daily; Week 5 and beyond: Increase by 50 mg daily every 1 to 2 weeks; Usual maintenance: 225 to 375 mg daily in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Regimens <b>containing</b> valproic acid:</i> Initial: Weeks 1 and 2: 25 mg every other day; Weeks 3 and 4: 25 mg once daily; Week 5 and beyond: Increase by 25 to 50 mg daily every 1 to 2 weeks; Usual maintenance: 100 to 200 mg daily (valproic acid alone) or 100 to 400 mg daily (valproic acid and other drugs that induce glucuronidation) in 1 or 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Regimens <b>containing</b> carbamazepine, phenytoin, phenobarbital, or primidone and without valproic acid:</i> Initial: Weeks 1 and 2: 50 mg once daily; Weeks 3 and 4: 100 mg daily in 2 divided doses; Week 5 and beyond: Increase by 100 mg daily every 1 to 2 weeks; Usual maintenance: 300 to 500 mg daily in 2 divided doses; maximum daily dose: 700 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">\n      <b>Partial seizures (adjunctive) and primary generalized tonic-clonic seizures (adjunctive):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release formulation:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Regimens <b>not containing</b> carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid:</i> Initial: Weeks 1 and 2: 25 mg once daily; Weeks 3 and 4: 50 mg once daily; Week 5 and beyond: Increase by 50 mg daily every 1 to 2 weeks; Usual maintenance: 225 to 375 mg daily in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Regimens <b>containing</b> valproic acid:</i> Initial: Weeks 1 and 2: 25 mg every other day; Weeks 3 and 4: 25 mg once daily; Week 5 and beyond: Increase by 25 to 50 mg daily every 1 to 2 weeks; Usual maintenance: 100 to 200 mg daily (valproic acid alone) or 100 to 400 mg daily (valproic acid and other drugs that induce glucuronidation) in 1 or 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Regimens <b>containing</b> carbamazepine, phenytoin, phenobarbital, or primidone and without valproic acid:</i> Initial: Weeks 1 and 2: 50 mg once daily; Weeks 3 and 4: 100 mg daily in 2 divided doses; Week 5 and beyond: Increase by 100 mg daily every 1 to 2 weeks; Usual maintenance: 300 to 500 mg daily in 2 divided doses; maximum daily dose: 700 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release formulation:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Regimens <b>not containing</b> carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid:</i> Initial: Weeks 1 and 2: 25 mg once daily; Weeks 3 and 4: 50 mg once daily; Week 5: 100 mg once daily; Week 6: 150 mg once daily; Week 7: 200 mg once daily; Week 8 and beyond: Dose increases should not exceed 100 mg daily at weekly intervals; Usual maintenance: 300 to 400 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Regimens <b>containing</b> valproic acid:</i> Initial: Weeks 1 and 2: 25 mg every other day; Weeks 3 and 4: 25 mg once daily; Week 5: 50 mg once daily; Week 6: 100 mg once daily; Week 7: 150 mg once daily; Week 8 and beyond: Dose increases should not exceed 100 mg daily at weekly intervals; Usual maintenance: 200 to 250 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Regimens <b>containing</b> carbamazepine, phenytoin, phenobarbital, or primidone and without valproic acid:</i> Initial: Weeks 1 and 2: 50 mg once daily; Weeks 3 and 4: 100 mg once daily; Week 5: 200 mg once daily; Week 6: 300 mg once daily; Week 7: 400 mg once daily; Week 8 and beyond: Dose increases should not exceed 100 mg daily at weekly intervals; Usual maintenance: 400 to 600 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Conversion strategy from adjunctive therapy with valproic acid to monotherapy with lamotrigine:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Immediate release formulation:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">- Initiate and titrate as per escalation recommendations for adjunctive therapy to a lamotrigine dose of 200 mg daily.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">- Then taper valproic acid dose in decrements of not &gt;500 mg/day/week to a valproic acid dosage of 500 mg daily; this dosage should be maintained for 1 week. The lamotrigine dosage should then be increased to 300 mg daily while valproic acid is simultaneously decreased to 250 mg daily; this dosage should be maintained for 1 week.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">- Valproic acid may then be discontinued, while the lamotrigine dose is increased by 100 mg daily at weekly intervals to achieve a lamotrigine maintenance dose of 500 mg daily in 2 divided doses.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Extended release formulation:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">- Initiate and titrate as per escalation recommendations for adjunctive therapy to a lamotrigine dose of 150 mg daily.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">- Then taper valproic acid dose in decrements of not &gt;500 mg/day/week to a valproic acid dose of 500 mg daily; this dosage should be maintained for 1 week. The lamotrigine dosage should then be increased to 200 mg daily while valproic acid is simultaneously decreased to 250 mg daily; this dosage should be maintained for 1 week.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">- Valproic acid may then be discontinued, while the lamotrigine dose is increased to achieve a maintenance dosage range of 250 to 300 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Conversion strategy from adjunctive therapy with carbamazepine, phenytoin, phenobarbital, or primidone to monotherapy with lamotrigine: Immediate release formulation and extended release formulation:</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">- Initiate and titrate as per escalation recommendations for adjunctive therapy to a lamotrigine dose of 500 mg daily.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">- Concomitant enzyme-inducing AED should then be withdrawn by 20% decrements each week over a 4-week period.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">- Two weeks after withdrawal of the enzyme-inducing AED, the dosage of lamotrigine extended release may be tapered in decrements of not &gt;100 mg/day at intervals of 1 week to achieve a maintenance dosage range of 250 to 300 mg once daily; no further dosage reduction is required for lamotrigine immediate release.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Conversion strategy from adjunctive therapy with AED other than carbamazepine, phenytoin, phenobarbital, primidone or valproic acid to monotherapy with lamotrigine:</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Immediate release formulation: No specific guidelines available</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Extended release formulation: Initiate and titrate as per escalation recommendations for adjunctive therapy to a lamotrigine dose of 250 to 300 mg daily. Concomitant AED should then be withdrawn by 20% decrements each week over a 4-week period.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Conversion from immediate release to extended release (Lamictal XR):</b> Initial dose of the extended release tablet should match the total daily dose of the immediate release formulation. Adjust dose as needed within the recommended dosing guidelines.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">\n      <b>Bipolar disorder:</b> Oral: Immediate release formulation:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Regimens <b>not containing</b> carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid:</i> Initial: Weeks 1 and 2: 25 mg once daily; Weeks 3 and 4: 50 mg once daily; Week 5: 100 mg once daily; Week 6 and maintenance: 200 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Regimens <b>containing</b> valproic acid:</i> Initial: Weeks 1 and 2: 25 mg every other day; Weeks 3 and 4: 25 mg once daily; Week 5: 50 mg once daily; Week 6 and maintenance: 100 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Regimens <b>containing</b> carbamazepine, phenytoin, phenobarbital, or primidone and without valproic acid:</i> Initial: Weeks 1 and 2: 50 mg once daily; Weeks 3 and 4: 100 mg daily in divided doses; Week 5: 200 mg daily in divided doses; Week 6: 300 mg daily in divided doses; Maintenance: Up to 400 mg daily in divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Adjustment following discontinuation of psychotropic medication:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Discontinuing valproic acid with current dose of lamotrigine 100 mg daily: 150 mg daily for week 1, then increase to 200 mg daily beginning week 2</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Discontinuing carbamazepine, phenytoin, phenobarbital, primidone, or rifampin with current dose of lamotrigine 400 mg daily: 400 mg daily for week 1, then decrease to 300 mg daily for week 2, then decrease to 200 mg daily beginning week 3</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment with concomitant atazanavir/ritonavir:</b> Adolescents: Follow initial lamotrigine dosing guidelines, maintenance dose should be adjusted as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">\n      <i>Patients <b>not taking</b> concomitant carbamazepine, phenytoin, phenobarbital, primidone, rifampin, estrogen-containing contraceptives, or lopinavir/ritonavir</i>: Lamotrigine maintenance dose may need to be increased if atazanavir/ritonavir is added or decreased if atazanavir/ritonavir is discontinued.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment with concomitant estrogen-containing oral contraceptives:</b> Adolescents: Follow initial lamotrigine dosing guidelines, maintenance dose should be adjusted as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Patients <b>taking</b> concomitant carbamazepine, phenytoin, phenobarbital, primidone, or other drugs, such as rifampin, that induce lamotrigine glucuronidation:</i> No dosing adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Patients <b>not taking</b> concomitant carbamazepine, phenytoin, phenobarbital, primidone, or other drugs, such as rifampin, that induce lamotrigine glucuronidation: </i>If already taking estrogen-containing oral contraceptives, the maintenance dose of lamotrigine may need to be increased by as much as twofold over the target maintenance dose listed above. If already taking a stable dose of lamotrigine and starting an oral contraceptive agent, the lamotrigine maintenance dose may need to be increased by as much as twofold. Dose increases should start when contraceptive agent is started and titrated to clinical response increasing no more rapidly than 50 to 100 mg/day every week. Gradual increases of lamotrigine plasma levels may occur during the inactive &ldquo;pill-free&rdquo; week and will be greater when dose increases are made the week before. If increased adverse events consistently occur during &ldquo;pill-free&rdquo; week, overall dose adjustments may be required. Dose adjustments during &ldquo;pill-free&rdquo; week are not recommended. When discontinuing combination hormonal contraceptive, dose of lamotrigine may need decreased by as much as 50%; do not decrease by more than 25% of total daily dose over a 2-week period unless clinical response or plasma levels indicate otherwise.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Additional considerations:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Discontinuing therapy:</i> Children &ge;2 years and Adolescents: Do not abruptly discontinue; when discontinuing lamotrigine therapy, gradually decrease the dose by ~50% per week and taper over at least 2 weeks unless safety concerns require a more rapid withdrawal. <b>Note:</b> If discontinuing other anticonvulsants and maintaining lamotrigine therapy, keep in mind that discontinuing carbamazepine, phenytoin, phenobarbital, primidone, or other drugs, such as rifampin, that induce lamotrigine glucuronidation should prolong the half-life of lamotrigine; discontinuing valproic acid should shorten the half-life of lamotrigine; monitor patient closely; dosage change may be needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Restarting therapy after discontinuation:</i> Children &ge;2 years and Adolescents: If lamotrigine has been withheld for &gt;5 half-lives, restart according to initial dosing recommendations. <b>Note:</b> Concomitant medications may affect the half-life of lamotrigine; consider pharmacokinetic interactions when restarting therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Use with caution; has not been adequately studied; base initial dose on patient&rsquo;s AED regimen; decreased maintenance dosage may be effective in patients with significant renal impairment; during a 4-hour hemodialysis period, ~20% is removed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> <b>Note:</b> Adjust escalation and maintenance doses by clinical response.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild hepatic impairment: No dosage adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate and severe hepatic impairment without ascites: Reduce initial, escalation, and maintenance doses by ~25%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe hepatic impairment with ascites: Reduce initial, escalation, and maintenance doses by 50%</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186277\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LaMICtal ODT: Blue Kit: 25 mg (21s) &amp; 50 mg (7s), Orange Kit: 25 mg (14s) &amp; 50 mg (14s) &amp; 100 mg (7s), Green Kit: 50 mg (42s) &amp; 100 mg (14s)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LaMICtal Starter: Blue Kit: 25 mg (35s)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LaMICtal Starter: Green Kit: 25 mg (84s) &amp; 100 mg (14s), Orange Kit: 25 mg (42s) &amp; 100 mg (7s) [contains fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LaMICtal XR: Green Kit: 50 mg (14s) &amp; 100 mg (14s) &amp; 200 mg (7s) [contains fd&amp;c blue #2 aluminum lake, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LaMICtal XR: Blue Kit: 25 mg (21s) &amp; 50 mg (7s), Orange Kit: 25 mg (14s) &amp; 50 mg (14s) &amp; 100 mg (7s) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: Blue Kit: 25 mg (21s) &amp; 50 mg (7s), Blue Kit: 25 mg (35s), Green Kit: 25 mg (84s) &amp; 100 mg (14s), Green Kit: 50 mg (42s) &amp; 100 mg (14s), Orange Kit: 25 mg (14s) &amp; 50 mg (14s) &amp; 100 mg (7s), Orange Kit: 25 mg (42s) &amp; 100 mg (7s)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LaMICtal: 25 mg, 100 mg, 150 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LaMICtal: 200 mg [scored; contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg, 100 mg, 150 mg, 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Chewable, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LaMICtal: 2 mg [DSC] [contains saccharin sodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LaMICtal: 5 mg [scored; berry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LaMICtal: 25 mg [berry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 25 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Disintegrating, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LaMICtal ODT: 25 mg, 50 mg, 100 mg, 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg, 50 mg, 100 mg, 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LaMICtal XR: 25 mg, 50 mg, 100 mg [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LaMICtal XR: 200 mg [contains fd&amp;c blue #2 aluminum lake, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LaMICtal XR: 250 mg [contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LaMICtal XR: 300 mg [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg, 50 mg, 100 mg, 200 mg, 250 mg, 300 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186262\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24530048\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">see &quot;Lamotrigine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;\">LaMICtal Kits are available as follows:</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">Blue - for patients already taking valproate</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">LaMICtal Starter: 25 mg (35s)</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">LaMICtal ODT (Titration): 25 mg (21s) and 50 mg (7s)</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">LaMICtal XR (Titration): 25 mg (21s) and 50 mg (7s)</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">Green- for patients already taking carbamazepine, phenytoin, phenobarbital, or primidone, and <b>not</b>  taking valproate</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">LaMICtal Starter: 25 mg (84s) and 100 mg (14s)</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">LaMICtal ODT (Titration): 50 mg (42s) and 100 mg (14s)</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">LaMICtal XR (Titration): 50 mg (14s) and 100 mg (14s) and 200 mg (7s)</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">Orange - for patients not taking carbamazepine, phenytoin, phenobarbital, primidone, or valproate</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">LaMICtal Starter: 25 mg (42s) and 100 mg (7s)</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">LaMICtal ODT (Titration): 25 mg (14s) and 50 mg (14s) and 100 mg (7s)</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">LaMICtal XR (Titration): 25 mg (14s) and 50 mg (14s) and 100 mg (7s)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874647\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information, and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lamictal, Lamictal ODT:  <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM152835.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+nIf162NgDrXSMpjxmnBPQica4o6qoIRpCq6pCRa11YQ==&amp;TOPIC_ID=12542\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM152835.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lamictal XR:  <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM166013.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+nIf162NgDrXSMpjxmnBPQZp+CMc1xxwyDziYOCFSmnA==&amp;TOPIC_ID=12542\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM166013.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053558\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Doses should be rounded down to the nearest whole tablet. May be administered without regard to food. If medication is received in blisterpack, examine blisterpack before use; do not use if blisters are broken, torn, or missing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Regular tablet: Do not chew, as a bitter taste may result; swallow tablet whole</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Chewable, dispersible tablet: Only whole tablets should be administered (tablets should not be cut or divided); may swallow whole, chew, or disperse in water or diluted fruit juice; if chewed, administer a small amount of water or diluted fruit juice to help in swallowing. If dispersed in a small amount of liquid, swirl the solution after tablet completely dispersed and administer entire amount immediately. Do not attempt to administer partial quantities of dispersed tablets.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Orally disintegrating tablet (Lamictal ODT): Place tablet on tongue and move around in the mouth. Tablet will dissolve rapidly and can be swallowed with or without food or water.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release tablet (Lamictal XR): May be administered without regard to meals. Swallow tablet whole; do not chew, crush, or break.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186299\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053557\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release: Tablets, chewable dispersible tablets, and orally disintegrating tablets: Adjunctive treatment of generalized seizures of Lennox-Gastaut syndrome, primary generalized tonic-clonic seizures, and partial seizures (FDA approved in ages &ge;2 years and adults); monotherapy of partial seizures in patients who are converted from valproic acid or a single enzyme-inducing AED (specifically, carbamazepine, phenytoin, phenobarbital, or primidone) (FDA approved in ages &ge;16 years and adults); maintenance treatment of bipolar I disorder (FDA approved in ages &ge;18 years and adults); has also been used as adjunctive treatment of partial seizures in ages &lt;24 months and monotherapy for absence seizures</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended-release tablets: Adjunctive treatment of primary generalized tonic-clonic seizures and partial onset seizures with or without secondary generalization (FDA approved in ages &ge;13 years and adults); monotherapy of partial seizures in patients who are converted from a single AED (FDA approved in ages &ge;13 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Has also been used as add-on therapy for atypical absence, atonic, tonic, and myoclonic seizures; and as monotherapy in adolescents for idiopathic generalized tonic-clonic seizures</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186355\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LamoTRIgine may be confused with labetalol, LamISIL, lamiVUDine, levETIRAcetam, levothyroxine, Lomotil</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LaMICtal may be confused with LamISIL, Lomotil</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Potential exists for medication errors to occur among different formulations of LaMICtal (tablets, extended release tablets, orally disintegrating tablets, and chewable/dispersible tablets). Patients should be instructed to visually inspect tablets dispensed to verify receiving the correct medication and formulation. The medication guide includes illustrations to aid in tablet verification. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Lamictal [US, Canada, and multiple international markets] may be confused with Ludiomil brand name for maprotiline [multiple international markets]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Lamotrigine [US, Canada, and multiple international markets] may be confused with Ludiomil brand name for maprotiline [multiple international markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186353\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Chest pain, edema, peripheral edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Abnormal dreams, abnormality in thinking, agitation, amnesia, anxiety, ataxia, confusion, depression, dizziness, drowsiness, dyspraxia, emotional lability, fatigue, hyperreflexia, hypoesthesia, hyporeflexia, insomnia, irritability, migraine, pain, paresthesia, suicidal ideation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash (nonserious is more common), dermatitis, diaphoresis, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Dysmenorrhea, weight gain, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, constipation, dyspepsia, flatulence, nausea, peptic ulcer, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Increased libido, urinary frequency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Rectal hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, myalgia, neck pain, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Amblyopia, nystagmus, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchitis, cough, dyspnea, epistaxis, nasopharyngitis, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abnormal hepatic function tests, abnormal lacrimation, accommodation disturbance, acne vulgaris, acute renal failure, ageusia, agranulocytosis, akathisia, alcohol intolerance, alopecia, altered sense of smell, amyotrophy, anemia, anorgasmia, apathy, aphasia, apnea, arthritis, aseptic meningitis, blepharoptosis, breast abscess, breast neoplasm, bursitis, central nervous system depression, cerebellar syndrome, conjunctivitis, cystitis, deafness, decreased fibrin, decreased libido, decreased serum fibrinogen, deep vein thrombophlebitis, delirium, delusions, depersonalization, depression, dermatitis (exfoliative, fungal), disseminated intravascular coagulation, DRESS syndrome, dry eye syndrome, dysphagia, dysphoria, dysuria, ecchymosis, ejaculatory disorder, eosinophilia, epididymitis, eructation, erythema multiforme, esophagitis, exacerbation of Parkinson disease, extrapyramidal reaction, gastritis, gastrointestinal hemorrhage, gingival hemorrhage, gingival hyperplasia, gingivitis, glossitis, hallucination, hemiplegia, hemorrhage, hepatitis, hepatotoxicity (idiosyncratic) (Chalasani, 2014), herpes zoster, hirsutism, hostility, hot flash, hyperalgesia, hyperbilirubinemia, hyperesthesia, hyperglycemia, hypermenorrhagia, hypersensitivity reaction, hypertension, hyperventilation, hypokinesia, hypothyroidism, hypotonia, immunosuppression (progressive), impotence, increased appetite, increased gamma glutamyl transpeptidase, increased serum alkaline phosphatase, increased serum ALT, increased serum AST, lactation, leg cramps, leukocytosis, leukoderma, leukopenia, lupus-like syndrome, lymphadenopathy, lymphocytosis, maculopapular rash, malaise, manic depressive reaction, memory impairment, multiorgan failure, muscle spasm, myasthenia, myoclonus, neuralgia, neutropenia, nightmares, oral mucosa ulcer, orthostatic hypotension, oscillopsia, otalgia, palpitations, pancreatitis, pancytopenia, panic attack, paralysis, paranoid reaction, pathological fracture, peripheral neuritis, personality disorder, petechia, photophobia, polyuria, psychosis, pure red cell aplasia, pustular rash, racing mind, renal pain, rhabdomyolysis, sialorrhea, skin discoloration, sleep disorder, status epilepticus, Stevens-Johnson syndrome, strabismus, suicidal tendencies, syncope, tachycardia, tendinous contracture, thrombocytopenia, tics, tinnitus, tonic-clonic seizures (exacerbation), urinary incontinence, urinary retention, urinary urgency, uveitis, vasculitis, vasodilation, vesiculobullous dermatitis, visual field defect, withdrawal syndrome (seizures with abrupt withdrawal)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186286\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity (eg, rash, angioedema, acute urticaria, extensive pruritus, mucosal ulceration) to lamotrigine or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186266\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Aseptic meningitis: Increased risk of developing aseptic meningitis has been reported; symptoms (eg, headache, nuchal rigidity, fever, nausea/vomiting, rash, photophobia) have generally occurred within 1 to 45 days following therapy initiation. In some cases, new onset hepatic, renal and/or other organ involvement has also occurred with symptoms, possibly suggesting aseptic meningitis is associated with a hypersensitivity reaction (eg, anticonvulsant hypersensitivity syndrome). Symptoms of aseptic meningitis generally resolve following discontinuation.  In some cases, re-exposure has resulted in a rapid return of symptoms (often more severe).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Blood dyscrasias: A spectrum of hematologic effects have been reported with use (eg, neutropenia, leukopenia, thrombocytopenia, pancytopenia, anemias, and rarely, aplastic anemia and pure red cell aplasia); patients with a previous history of adverse hematologic reaction to any drug may be at increased risk. Early detection of hematologic change is important; advise patients of early signs and symptoms including fever, sore throat, mouth ulcers, infections, easy bruising, petechial or purpuric hemorrhage. May be associated with hypersensitivity syndrome.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Multiorgan hypersensitivity reactions (drug reaction with eosinophilia and systemic symptoms [DRESS]): Potentially serious, sometimes fatal, multiorgan hypersensitivity reactions (DRESS) have been reported with some antiepileptic drugs (rare). Symptoms may include fever, rash, and/or lymphadenopathy; monitor for signs and symptoms of possible disparate manifestations associated with lymphatic, hepatic, renal, and/or hematologic organ systems. Early symptoms of hypersensitivity reaction (eg, lymphadenopathy, fever) may occur without rash; discontinuation and conversion to alternate therapy may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Skin reactions: <b>[US Boxed Warning]:  Serious skin rashes requiring hospitalization and discontinuation of treatment have been reported; incidence of serious rash is higher in pediatric patients than adults; risk may be increased by coadministration with valproic acid, higher than recommended  initial doses, exceeding recommended initial dose titration, or exceeding the recommended dose escalation for lamotrigine. One rash-related death was reported in a pediatric patients taking lamotrigine immediate-release as adjunctive therapy. Nearly all cases of life-threatening rashes associated with lamotrigine have occurred within 2 to 8 weeks of treatment initiation; however, isolated cases may occur after prolonged treatment (eg, 6 months) or in patients without these risk factors; discontinue at first sign of rash and do not reinitiate therapy unless rash is clearly not drug related. Rare cases of toxic epidermal necrolysis and/or rash-related death have been reported. Discontinuation of treatment may not prevent a rash from becoming life-threatening or permanently disabling or disfiguring. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify healthcare provider immediately if symptoms occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustment may be required. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment may be required. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: Children are at increased risk for developing serious skin rashes during therapy; lower starting doses and slower dose escalations may decrease the risk of rash. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson, 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade, 1986; CDC, 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Bipolar disorder use: Patients treated for bipolar disorder should be monitored closely for clinical worsening or suicidality; reassess patients to determine the need for maintenance treatment if on therapy &gt;16 weeks. Prescriptions should be written for the smallest quantity consistent with good patient care. Treatment of acute manic or mixed episodes is not recommended; efficacy has not been established and slow titration limits use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Medication error potential: Medication errors have occurred; potential for medication errors with similar-sounding medications and between different lamotrigine formulations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Melanin binding: Binds to melanin and may accumulate in the eye and other melanin-rich tissues; the clinical significance of this is not known. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Monotherapy: Epilepsy: Safety and efficacy have not been established for use as initial monotherapy, conversion to monotherapy from antiepileptic drugs (AED) other than carbamazepine, phenytoin, phenobarbital, primidone or valproic acid or conversion to monotherapy from two or more AEDs. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal. Taper over at least 2 weeks if possible. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26021946\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Incidence of serious rash is higher in pediatric patients than adults. Serious skin rashes (including Stevens-Johnson syndrome) occur in 0.8% of pediatric epilepsy patients (2 to 16 years of age) and 0.3% of adult epilepsy patients and in up to 0.13% of adult patients treated for bipolar and other mood disorders; rare cases of toxic epidermal necrolysis and angioedema have been reported; rash-related deaths have occurred in pediatric and adult patients. In addition to pediatric age, the risk of rash may be increased in patients receiving valproic acid, high initial doses, or with rapid dosage increases; however, rash has been reported in patients without risk factors. Rash usually appears in the first 2 to 8 weeks of therapy, but may occur after prolonged treatment (eg, 6 months). Benign rashes may occur, but one cannot predict which rashes will become serious or life-threatening; the manufacturer recommends (ordinarily) discontinuation of lamotrigine at the first sign of rash (unless rash is clearly not drug related); discontinuation of lamotrigine may not prevent rash from becoming life-threatening or permanently disfiguring or disabling. Risk of nonserious rash may also be increased when the initial recommended dose or dose escalation rate is exceeded in patients with a history of rash or allergy to other AEDs.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Do not abruptly discontinue; when discontinuing therapy, gradually reduce the dose by ~50% per week and taper over at least 2 weeks unless safety concerns require a more rapid withdrawal. Lamotrigine should not be restarted in patients who discontinued therapy due to lamotrigine-associated rash, unless benefits clearly outweigh risks; if restarting lamotrigine after withholding for &gt;5 half-lives, use the initial dosing recommendations and titrate dosage accordingly (ie, do not restart at the previous maintenance dose). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A small randomized, double-blind, placebo-controlled study in pediatric patients 1 to 24 months of age did not demonstrate safety and efficacy of immediate release lamotrigine when used as adjunctive treatment for partial seizures; lamotrigine was associated with an increased risk for infectious and respiratory adverse reactions. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299573\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> OCT2</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186271\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12542&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acetaminophen: May decrease the serum concentration of LamoTRIgine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: May decrease the serum concentration of LamoTRIgine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May decrease the serum concentration of LamoTRIgine. Management: See lamotrigine prescribing information for specific age-dependent dosing guidelines regarding concurrent use with a barbiturate, as well as for adjusting lamotrigine dosing if concurrent barbiturate therapy is discontinued.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: LamoTRIgine may enhance the adverse/toxic effect of CarBAMazepine. CarBAMazepine may increase the metabolism of LamoTRIgine. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: LamoTRIgine may enhance the adverse/toxic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dofetilide: LamoTRIgine may increase the serum concentration of Dofetilide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May decrease the serum concentration of LamoTRIgine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): May decrease the serum concentration of LamoTRIgine. Management: Monitor for increased serum concentrations/effects of lamotrigine in patients in whom a hormonal contraceptive is discontinued/dose decreased (this includes during a pill-free week). A reduced dosage of lamotrigine may be needed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ezogabine: May decrease the serum concentration of LamoTRIgine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of LamoTRIgine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetFORMIN: LamoTRIgine may increase the serum concentration of MetFORMIN.  Management: The lamotrigine Canadian product monograph states that coadministration of these drugs is not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May diminish the therapeutic effect of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OLANZapine: LamoTRIgine may enhance the sedative effect of OLANZapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of LamoTRIgine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Primidone: May decrease the serum concentration of LamoTRIgine. Management: Adjust dose per lamotrigine prescribing information guidelines during primidone treatment.  Monitor for decreased concentration/effect if primidone is initiated/dose increased or increased concentration/effect if primidone is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Procainamide: LamoTRIgine may increase the serum concentration of Procainamide.  Management: Consider monitoring for increased procainamide concentrations and/or systemic effects in patients receiving procainamide with lamotrigine.  The lamotrigine Canadian product monograph states that coadministration of these agents is not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): LamoTRIgine may decrease the serum concentration of Progestins (Contraceptive). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May increase the metabolism of LamoTRIgine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May decrease the serum concentration of LamoTRIgine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulthiame: May increase the serum concentration of LamoTRIgine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: May enhance the adverse/toxic effect of LamoTRIgine. Valproate Products may increase the serum concentration of LamoTRIgine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186300\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food has no effect on absorption. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186273\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186289\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Lamotrigine crosses the human placenta and can be measured in the plasma of exposed newborns (Harden and Pennell 2009; Ohman 2000). An overall increase in the risk for major congenital malformations has not been observed in available studies; however, an increased risk for cleft lip or cleft palate has not been ruled out (Cunnington 2011; Hern&aacute;ndez-D&iacute;az 2012; Holmes 2012). An increased risk of malformations following maternal lamotrigine use may be associated with larger doses (Cunnington 2007; Tomson 2011). Polytherapy may increase the risk of congenital malformations; monotherapy with the lowest effective dose is recommended (Harden and Meader 2009).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Due to pregnancy-induced physiologic changes, women who are pregnant may require dose adjustments of lamotrigine in order to maintain clinical response; monitoring during pregnancy should be considered (Harden and Pennell 2009). For women with epilepsy who are planning a pregnancy in advance, baseline serum concentrations should be measured once or twice prior to pregnancy during a period when seizure control is optimal. Monitoring can then be continued up to once a month during pregnancy and every second day during the first week postpartum (Patsalos 2008). In women taking lamotrigine who are trying to avoid pregnancy, potentially significant interactions may exist with hormone-containing contraceptives; consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Pregnancy registries are available for women who have been exposed to lamotrigine. Patients may enroll themselves in the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling (888) 233-2334. Additional information is available at www.aedpregnancyregistry.org.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053552\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">All patients: Monitor for hypersensitivity reactions, especially rash; CBC with differential; liver and renal function </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Epilepsy: Seizure frequency, duration, and severity; serum levels of concurrent anticonvulsants; signs and symptoms of suicidality (eg, anxiety, depression, behavior changes) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bipolar disorder: Clinical worsening of depressive symptoms or suicidality, especially with initiation of therapy or dosage changes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053556\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">The clinical value of monitoring lamotrigine plasma concentrations has not been established. Dosing should be based on therapeutic response. Proposed therapeutic range: 1 to 5 mcg/mL. Lamotrigine plasma concentrations of 0.25-29.1 mcg/mL have been reported in the literature.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186265\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">A triazine derivative which inhibits release of glutamate (an excitatory amino acid) and inhibits voltage-sensitive sodium channels, which stabilizes neuronal membranes. Lamotrigine has weak inhibitory effect on the 5-HT<sub>3</sub> receptor; <i>in vitro</i> inhibits dihydrofolate reductase.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186285\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Immediate release: Rapid and complete, 97.6% absorbed; <b>Note:</b> Orally disintegrating tablets (either swallowed whole with water or disintegrated in the mouth) are equivalent to regular tablets (swallowed whole with water) in terms of rate and extent of absorption. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 1.1 L/kg; range: 0.9 to 1.3 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~55% (primarily albumin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic and renal; &gt;75% metabolized via glucuronidation; autoinduction may occur</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Immediate release: 98%; <b>Note:</b> AUCs were similar for immediate release and extended release preparations in patients receiving nonenzyme-inducing AEDs. In subjects receiving concomitant enzyme-inducing AEDs, bioavailability of extended release product was ~21% lower than immediate release product; in some of these subjects, a decrease in AUC of up to 70% was observed when switching from immediate release to extended release tablets.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pediatric patients:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">No concomitant enzyme-inducing AED (ie, phenytoin, phenobarbital, carbamazepine, primidone): Infants and Children 10 months to 5 years: 19 hours (range: 13 to 27 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Concomitant valproate derivative therapy:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Infants and Children 10 months to 5 years: 45 hours (range: 30 to 52 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children 5 to 11 years: 66 hours (50 to 74 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Concomitant enzyme-inducing AEDs (ie, phenytoin, phenobarbital, carbamazepine, primidone):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Infants and Children 10 months to 5 years: 7.7 hours (range: 6 to 11 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children 5 to 11 years: 7 hours (range: 4 to 10 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Concomitant enzyme-inducing AEDs plus valproate derivative therapy: Children 5 to 11 years: 19 hours (range: 7 to 31 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Immediate release: 25 to 33 hours, Elderly: 25 to 43 hours; Extended release: Similar to immediate release</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Concomitant valproic acid therapy: 48 to 70 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Concomitant phenytoin, phenobarbital, primidone, or carbamazepine therapy: 13 to 14 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Concomitant phenytoin, phenobarbital, primidone, or carbamazepine plus valproate therapy: 27 hours</p>\n    <p style=\"text-indent:-4em;margin-left:8em;text-align:justify;\">Chronic renal failure: 43 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Hemodialysis: 13 hours during dialysis; 57 hours between dialysis (~20% of a dose is eliminated in a 4-hour dialysis session)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Hepatic impairment:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Mild: 46 &plusmn; 20 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Moderate: 72 &plusmn; 44 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Severe without ascites: 67 &plusmn; 11 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Severe with ascites: 100 &plusmn; 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: Immediate release: ~1 to 5 hours (dependent on adjunct therapy); Extended release: 4 to 11 hours (dependent on adjunct therapy) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (94%, ~90% as glucuronide conjugates and ~10% unchanged); feces (2%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186284\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">A 1 mg/mL oral suspension may be made with tablets and one of two different vehicles (a 1:1 mixture of Ora-Sweet and Ora-Plus or a 1:1 mixture of Ora-Sweet SF and Ora-Plus). Crush one 100 mg tablet in a mortar and reduce to a fine powder. Add small portions of the chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 100 mL; transfer to a graduated cylinder, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 100 mL. Label &quot;shake well&quot; and &quot;protect from light&quot;. Stable for 91 days when stored in amber plastic prescription bottles in the dark at room temperature or refrigerated.</p>\n    <div class=\"reference\">Nahata M, Morosco R, Hipple T. &ldquo;Stability of Lamotrigine in Two Extemporaneously Prepared Oral Suspensions at 4 and 25 Degrees C,&rdquo; <i>Am J Health Syst Pharm</i>, 1999, 56(3):240-2.<span class=\"pubmed-id\">10030509</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186288\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (LaMICtal Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $1,439.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $1,545.65</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (LamoTRIgine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $305.33</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $319.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (LaMICtal ODT Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 (21)-50 (7) mg (28): $438.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 &amp; 50 &amp; 100 mg (35): $625.81</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 (42)-100(14) mg (56): $1,251.58</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (LaMICtal Starter Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 (35) mg (35): $520.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 (42)-100 (7) mg (49): $743.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 (84)-100(14) mg (98): $1,487.84</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (LaMICtal XR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 (21)-50 (7) mg (28): $458.05</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 &amp; 50 &amp; 100 mg (35): $654.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 &amp; 100 &amp; 200 mg (35): $1,308.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (LamoTRIgine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 (21)-50 (7) mg (28): $344.37</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 &amp; 50 &amp; 100 mg (35): $491.91</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 (42)-100(14) mg (56): $983.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (LaMICtal XR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (30): $392.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (30): $785.15</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $841.02</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (30): $896.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (30): $1,223.02</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (30): $1,345.31</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (LamoTRIgine ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (30): $196.43</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (30): $392.81</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $420.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (30): $448.70</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (30): $611.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (30): $673.07</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, orally-disintegrating</b> (LaMICtal ODT Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (30): $375.54</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (30): $402.24</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $428.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (30): $511.81</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, orally-disintegrating</b> (LamoTRIgine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (30): $266.29</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (30): $285.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $304.13</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (30): $362.91</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (LaMICtal Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $1,487.99</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $1,699.67</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (60): $1,117.73</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (60): $1,216.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (LamoTRIgine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $415.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $475.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (60): $312.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (60): $340.15</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186291\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Arvind (HR);</li>\n      <li>Epictal (JO);</li>\n      <li>Labicitin (KR);</li>\n      <li>Lafigin (PY);</li>\n      <li>Lamal (UA);</li>\n      <li>Lamdra SBK (MX);</li>\n      <li>Lamepil (IN);</li>\n      <li>Lameptil (BD);</li>\n      <li>Lametec (CO);</li>\n      <li>Lamicet (BD);</li>\n      <li>Lamictal (AE, AR, AT, AU, BB, BD, BE, BG, BH, BM, BO, BR, BS, BZ, CH, CL, CN, CO, CR, CU, CY, CZ, DE, DK, DO, EC, EE, EG, ES, FI, FR, GB, GR, GT, GY, HK, HN, HR, HU, ID, IE, IL, IQ, IR, IS, IT, JM, JO, JP, KR, KW, LB, LT, LU, LV, LY, MT, MX, MY, NI, NL, NO, NZ, OM, PA, PE, PH, PK, PL, PR, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, SR, SV, SY, TH, TR, TT, TW, UY, VE, VN, YE);</li>\n      <li>Lamidus (AU, TW);</li>\n      <li>Lamidus DT (LK);</li>\n      <li>Lamiktal (UA);</li>\n      <li>Lamiros (ID);</li>\n      <li>Lamitor (AE, PH);</li>\n      <li>Lamitor DT-25 (ET);</li>\n      <li>Lamitrin (BD);</li>\n      <li>Lamodex (IL);</li>\n      <li>Lamoga (TH);</li>\n      <li>Lamogin (CO, TW);</li>\n      <li>Lamogine (IL);</li>\n      <li>Lamolental (UA);</li>\n      <li>Lamor (JO);</li>\n      <li>Lamoro (IE);</li>\n      <li>Lamostad (VN);</li>\n      <li>Lamosyn (PH);</li>\n      <li>Lamotrin (HK);</li>\n      <li>Lamotrix (LK, LV, MY, PH, QA, SG, TW, VN);</li>\n      <li>Lamox (HR);</li>\n      <li>Larig (IE);</li>\n      <li>Latrigine (TW);</li>\n      <li>Latrin (EC);</li>\n      <li>Lepigine (LB);</li>\n      <li>Lojin (LK);</li>\n      <li>Loxol (JO, QA);</li>\n      <li>Mibedos (VN);</li>\n      <li>Mogine (NZ);</li>\n      <li>Motrigine (PH);</li>\n      <li>Protalgine (MX);</li>\n      <li>Seaze (AU);</li>\n      <li>Tevalamotrigine Chew Tab (KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamotrigine-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barr PA, Buettiker VE, and Antony JH, &quot;Efficacy of Lamotrigine in Refractory Neonatal Seizures,&quot; <i>Pediatr Neurol</i>, 1999, 20(2):161-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamotrigine-pediatric-drug-information/abstract-text/10082350/pubmed\" target=\"_blank\" id=\"10082350\">10082350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Battino D, Estienne M, and Avanzini G, &ldquo;Clinical Pharmacokinetics of Antiepileptic Drugs in Paediatric Patients: Part II. Phenytoin, Carbamazepine, Sulthiame, Lamotrigine, Vigabatrin, Oxcarbazepine, and Felbamate,&rdquo; <i>Clin Pharmacokinet</i>, 1995, 29(5):341-69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamotrigine-pediatric-drug-information/abstract-text/8582119 /pubmed\" target=\"_blank\" id=\"8582119 \">8582119 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Besag FM, Wallace SJ, Dulac O, et al, &ldquo;Lamotrigine for the Treatment of Epilepsy in Childhood,&rdquo; <i>J Pediatr</i>, 1995, 127(6):991-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamotrigine-pediatric-drug-information/abstract-text/8523205/pubmed\" target=\"_blank\" id=\"8523205\">8523205</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burstein AH, &ldquo;Lamotrigine,&rdquo; <i>Pharmacotherapy</i>, 1995, 15(2):129-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamotrigine-pediatric-drug-information/abstract-text/7624259/pubmed\" target=\"_blank\" id=\"7624259\">7624259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coppola G, Auricchio G, Federico R, Carotenuto M, Pascotto A. Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. <i>Epilepsia</i>. 2004;45(9):1049-1053.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamotrigine-pediatric-drug-information/abstract-text/15329068/pubmed\" target=\"_blank\" id=\"15329068\">15329068</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cunnington M, Ferber S, Quartey G, et al, &quot;Effect of Dose on the Frequency of Major Birth Defects Following Fetal Exposure to Lamotrigine Monotherapy in an International Observational Study,&quot; <i>Epilepsia</i>, 2007, 48(6):1207-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamotrigine-pediatric-drug-information/abstract-text/17381445/pubmed\" target=\"_blank\" id=\"17381445\">17381445</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cunnington MC, Weil JG, Messenheimer JA, et al, &quot;Final Results From 18 Years of the International Lamotrigine Pregnancy Registry,&quot; <i>Neurology</i>, 2011, 76(21):1817-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamotrigine-pediatric-drug-information/abstract-text/21606453/pubmed\" target=\"_blank\" id=\"21606453\">21606453</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dooley J, Camfield P, Gordon K, et al, &ldquo;Lamotrigine-Induced Rash in Children,&rdquo; <i>Neurology</i>, 1996, 46(1):240-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamotrigine-pediatric-drug-information/abstract-text/8559384 /pubmed\" target=\"_blank\" id=\"8559384 \">8559384 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fitton A, and Goa KL, &ldquo;Lamotrigine: An Update of its Pharmacology and Therapeutic Use in Epilepsy,&rdquo; <i>Drugs</i>, 1995, 50(4):691-713.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamotrigine-pediatric-drug-information/abstract-text/8536554/pubmed\" target=\"_blank\" id=\"8536554\">8536554</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frank LM, Enlow T, Holmes GL, et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. <i>Epilepsia</i>. 1999;40(7):973-979.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamotrigine-pediatric-drug-information/abstract-text/10403222/pubmed\" target=\"_blank\" id=\"10403222\">10403222</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. <i>N Engl J Med</i>. 2010;362(9):790-799.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamotrigine-pediatric-drug-information/abstract-text/20200383/pubmed\" target=\"_blank\" id=\"20200383\">20200383</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. <i>Epilepsia</i>. 2013;54(1):141-155.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamotrigine-pediatric-drug-information/abstract-text/23167925/pubmed\" target=\"_blank\" id=\"23167925\">23167925</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harden CL, Meador KJ, Pennell PB, et al, &quot;Practice Parameter Update: Management Issues for Women With Epilepsy-Focus on Pregnancy (an Evidence-Based Review): Teratogenesis and Perinatal Outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society,&quot; <i>Neurology</i>, 2009, 73(2):133-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamotrigine-pediatric-drug-information/abstract-text/19398681/pubmed\" target=\"_blank\" id=\"19398681\">19398681</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harden CL, Pennell PB, Koppel BS, et al, &quot;Practice Parameter Update Management Issues for Women With Epilepsy-Focus on Pregnancy (an Evidence-Based Review): Vitamin K, Folic Acid, Blood Levels, and Breastfeeding: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society,&quot; <i>Neurology</i>, 2009, 73(2):142-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamotrigine-pediatric-drug-information/abstract-text/19398680/pubmed\" target=\"_blank\" id=\"19398680\">19398680</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hern&aacute;ndez-D&iacute;az S, Smith CR, Shen A, et al, &quot;Comparative Safety of Antiepileptic Drugs During Pregnancy,&quot; <i>Neurology</i>, 2012, 78(21):1692-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamotrigine-pediatric-drug-information/abstract-text/22551726/pubmed\" target=\"_blank\" id=\"22551726\">22551726</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holmes LB and Hern&aacute;ndez-D&iacute;az S, &quot;Newer Anticonvulsants: Lamotrigine, Topiramate and Gabapentin,&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2012, 94(8):599-606.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamotrigine-pediatric-drug-information/abstract-text/22730257/pubmed\" target=\"_blank\" id=\"22730257\">22730257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47:313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamotrigine-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lamictal (lamotrigine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lamictal XR (lamotrigine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Messenheimer JA, &ldquo;Lamotrigine,&rdquo; <i>Epilepsia</i>, 1995, 36(Suppl 2):S87-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamotrigine-pediatric-drug-information/abstract-text/8784217/pubmed\" target=\"_blank\" id=\"8784217\">8784217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Messenheimer JA, Giorgi L, and Risner ME, &ldquo;The Tolerability of Lamotrigine in Children,&rdquo; <i>Drug Saf</i>, 2000, 22(4):303-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamotrigine-pediatric-drug-information/abstract-text/10789824/pubmed\" target=\"_blank\" id=\"10789824\">10789824</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mikati MA, Fayad M, Koleilat M, et al, &quot;Efficacy, Tolerability, and Kinetics of Lamotrigine in Infants,&quot; <i>J Pediatr</i>, 2002, 141(1):31-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamotrigine-pediatric-drug-information/abstract-text/12091848/pubmed\" target=\"_blank\" id=\"12091848\">12091848</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Newport DJ, Pennell PB, Calamaras MR, et al. Lamotrigine in breast milk and nursing infants: determination of exposure. <i>Pediatrics</i>. 2008;122(1):e223-231.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamotrigine-pediatric-drug-information/abstract-text/18591203/pubmed\" target=\"_blank\" id=\"18591203\">18591203</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nordmo E, Aronsen L, Wasland K, Sm&aring;brekke L, Vorren S. Severe apnea in an infant exposed to lamotrigine in breast milk. <i>Ann Pharmacother</i>. 2009;43(11):1893-1897.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamotrigine-pediatric-drug-information/abstract-text/19826099/pubmed\" target=\"_blank\" id=\"19826099\">19826099</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ohman I, Vitols S, and Tomson T, &ldquo;Lamotrigine in Pregnancy: Pharmacokinetics During Delivery, in the Neonate, and During Lactation,&rdquo; <i>Epilepsia</i>, 2000, 41(6):709-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamotrigine-pediatric-drug-information/abstract-text/10840403/pubmed\" target=\"_blank\" id=\"10840403\">10840403</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patsalos PN, Berry DJ, Bourgeois BF, et al, &quot;Antiepileptic Drugs-Best Practice Guidelines for Therapeutic Drug Monitoring: A Position Paper by the Subcommission on Therapeutic Drug Monitoring, ILAE Commission on Therapeutic Strategies,&quot; <i>Epilepsia</i>, 2008, 49(7):1239-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamotrigine-pediatric-drug-information/abstract-text/18397299/pubmed\" target=\"_blank\" id=\"18397299\">18397299</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pi&ntilde;a-Garza JE, Elterman RD, Ayala R, et al, &quot;Long-Term Tolerability and Efficacy of Lamotrigine in Infants 1 to 24 Months Old,&quot; <i>J Child Neurol</i>, 2008, 23(8):853-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamotrigine-pediatric-drug-information/abstract-text/18660469/pubmed\" target=\"_blank\" id=\"18660469\">18660469</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pi&ntilde;a-Garza JE, Levisohn P, Gucuyener K, et al, &quot;Adjunctive Lamotrigine for Partial Seizures in Patients Aged 1 to 24 Months,&quot; <i>Neurology</i>, 2008a, 70(22 Pt 2):2099-108.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamotrigine-pediatric-drug-information/abstract-text/18077797/pubmed\" target=\"_blank\" id=\"18077797\">18077797</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Popescu L, Marceanu M, Moleavin I. Withdrawal of lamotrigine caused by sudden weaning of a newborn: a case report. <i>Epilepsia</i> 2005;46 (Suppl 6):407. (Abstract p. 1351.)</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Soussan C, Gouraud A, Portolan G, et al. Drug-induced adverse reactions via breastfeeding: a descriptive study in the French Pharmacovigilance Database. <i>Eur J Clin Pharmacol</i>. 2014;70(11):1361-1366.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamotrigine-pediatric-drug-information/abstract-text/25183382/pubmed\" target=\"_blank\" id=\"25183382\">25183382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tomson T, Battino D, Bonizzoni E, et al, &quot;Dose-Dependent Risk of Malformations With Antiepileptic Drugs: An Analysis of Data From the EURAP Epilepsy and Pregnancy Registry,&quot; <i>Lancet Neurol</i>, 2011, 10(7):609-17.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wakil L, Epperson CN, Gonzalez J, O'Reardon JP, Kim DR. Neonatal outcomes with the use of lamotrigine for bipolar disorder in pregnancy and breastfeeding: a case series and review of the literature. <i>Psychopharmacol Bull</i>. 2009;42(3):91-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lamotrigine-pediatric-drug-information/abstract-text/19752842/pubmed\" target=\"_blank\" id=\"19752842\">19752842</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12542 Version 227.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709006\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F186304\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F186305\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1053553\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F12675197\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1053546\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F186277\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F186262\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F24530048\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874647\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1053558\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F186299\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1053557\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F186355\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F186353\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F186286\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F186266\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26021946\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299573\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F186271\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F186300\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F186273\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F186289\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1053552\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1053556\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F186265\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F186285\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F186284\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F186288\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F186291\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12542|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">Lamotrigine: Drug information</a></li><li><a href=\"topic.htm?path=lamotrigine-patient-drug-information\" class=\"drug drug_patient\">Lamotrigine: Patient drug information</a></li></ul></div></div>","javascript":null}